Navigation Links
Royalty Pharma Announces that Alexander von Perfall Joins Management Team
Date:12/7/2009

NEW YORK, Dec. 7 /PRNewswire/ -- Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO)

Alexander has 13 years of cross-border management advisory, strategic planning and principal investment experience, most recently as co-founder and Chief Network Officer of XTF, a start-up Exchange Traded Funds Ratings Agency. He previously advised the International Finance Corporation/World Bank Group on the syndication of media sector private equity investments. Alexander started his career with Bertelsmann AG where he held various management positions, culminating with a position as Director of Business Development where he initiated and oversaw investments in a number of early stage media and entertainment ventures. Alexander attended the Hoschchule St. Gallen in Switzerland before obtaining a BA in Politics from the University of San Francisco and an MBA from the New York University - Stern School of Business.

"The addition of Alexander to our management team adds an important element of investor relationship management," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "Alexander will play a key role in Royalty Pharma's efforts to enhance its investor and key stakeholder strategy and communication, including acting as a liaison between Royalty Pharma's management team and equity and debt investors, the analyst community and media representatives."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property - principally royalty interests in marketed and late stage biopharmaceutical products with approximately $6 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including Abbott's Humira®, J&J/Merck's Remicade®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Gilead's Emtriva®, Truvada® and Atripla®, and Celgene's Thalomid®. Royalty Pharma has a thirteen year history of providing value to holders of royalty interests, including its $700 million purchase of the Lyrica® royalty from Northwestern University, its $650 million purchase of the Remicade® royalty from New York University, its $700 million purchase of the Humira® royalty from AstraZeneca plc following its acquisition of Cambridge Antibody Technology, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen® and Neulasta® for over $400 million. For more information, go to www.royaltypharma.com.


For additional information, please contact:
Pablo Legorreta                                Alexander v. Perfall
Chief Executive Officer                        VP, Investor Relations
+ 1 (212) 883-2288                             + 1 (212) 883-2298
plegorreta@royaltypharma.com                   aperfall@royaltypharma.com

More information on Royalty Pharma is available at www.royaltypharma.com.

SOURCE Royalty Pharma


'/>"/>
SOURCE Royalty Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
2. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
3. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting
8. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
9. Amber Pharmacy Earns Accreditation From ACHC
10. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
11. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Little Rock, AR (PRWEB) , ... October 13, ... ... owned firm with locations throughout Arkansas that offers insurance and financial preparation services, ... to benefit the Rock City Rescue organization. , Rock City Rescue is a ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
Breaking Medicine News(10 mins):